

B2
ended

least one striated muscle cell with at least one unipolar pulse of an electric field intensity ranging from 1 to 800 V/cm².

116. A method of producing expression of neurotrophin 3 (NT3) *in vivo* in striated muscle comprising: contacting *in vivo* at least one striated muscle cell with at least one nucleic acid encoding said NT3; and electrically stimulating said at least one striated muscle cell with at least one unipolar pulse of an electric field intensity ranging from 1 to 800 V/cm².

117. A method of producing expression of human growth hormone *in vivo* in striated muscle comprising: contacting *in vivo* at least one striated muscle cell with at least one nucleic acid encoding said human growth hormone; and electrically stimulating said at least one striated muscle cell with at least one unipolar pulse of an electric field intensity ranging from 1 to 800 V/cm².

REMARKS

With entry of this amendment, claims 85-117 are now pending in this application.

Support for the amendments can be found in the specification as filed. For example, support for the methods of

claims 85 and 114 may be found on page 10, line 1-4, page 14, line 12-13, and page 71, Example 20;

claims 104 and 111 may be found on page 13, line 25 and page 72, Example 21;

claims 107 and 116 may be found on page 14, line 15 and page 76, Example 23;

claims 109 and 113 may be found on page 15, lines 1-2 and page 69,

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

claims 109 and 113 may be found on page 15, lines 1-2 and page 69,
Example 19; and


claims 112, 115, and 117, on page 66, Example 18, page 74, Example 22, and
page 79, Example 24, respectively.

No new matter has been added and none of the claims has been amended to
overcome prior art. Claims 1-84 are cancelled without prejudice to or disclaimer thereof
and Applicants reserve the right to pursue claims of similar scope in another application.

CONCLUSION

If there are any additional fees due in connection with the filing of this Preliminary
Amendment, please charge the fees to our Deposit Account No. 06-0916. If a fee is
required for an extension of time under 37 C.F.R. § 1.136 not accounted for above,
such an extension is requested and the fee should also be charged to our Deposit
Account.

Respectfully submitted,
FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER

By: 
Steven P. O'Connor
Reg. No. 41,225

Date: November 7, 2001